Table 4

 Cumulative major outcomes, quality adjusted life years lost, and costs expected over 10 years, the incremental cost per outcome for each screening strategy, and the average cost per outcome (compared to no screening) for each assumption about pelvic inflammatory disease (PID) progression: PID = 10%

Total MOTotal QALYs lostTotal cost (£)Incremental cost(£)/MOAIncremental cost (£)/QALY gainedAverage cost (£)/MOAAverage cost (£)/QALY gained
MO, major outcome; MOA, major outcomes averted. Values in the table are rounded for presentation. QALY, quality adjusted life years; All costs and effects are discounted at 3.5%. Results are presented in rank order of total costs, which include costs of infection, complications, and programme costs. Dominated means that the MOA or QALYs gained is less than the non-dominated strategy above it in the table.
Baseline, noscreening139265310 695––––
Strategy 1 <2088339553 35247792044779204
Strategy 2 <2073631771 367148429 41670313 640
Strategy 3 <2067329832 49895924 10372614 371
Strategy 1 <2573932918 213DominatedDominated93018 476
Strategy 1 <30645281 283 62816 415978 039130326 459
Strategy 2 <25584241 462,494292844 109142628 212
Strategy 3 <25468191 556 57280719 352134827 269
Strategy 1 <35633281 666 599DominatedDominated178836 849
Strategy 1 <40610282 048 769DominatedDominated222446 404
Strategy 2 <30491202 157 585DominatedDominated205141 470
Strategy 3 <30400172 308 02311 059302 328201341 461
Strategy 2 <35460202 869 275DominatedDominated274556 481
Strategy 3 <35363163 064 43220 479747 964267655 987
Strategy 2 <40444203 582 115DominatedDominated345371 953
Strategy 3 <40343153 828 43239 2301 938 410335570 952